Rheos is advancing a deep pipeline of therapies aimed at novel and differentiated targets.
The combination of our fundamental understanding of immunometabolism and our target validation and drug development capabilities position us to bring forward a new class of medicines.
Information on Roche partnership
In December 2019, Rheos established a multi-target discovery, development, and commercialization collaboration with Roche. Our shared objective is to identify and develop new immunometabolic therapeutics for autoimmune and inflammatory diseases.